Q1 Earnings Estimate for FibroGen Issued By HC Wainwright

FibroGen, Inc. (NASDAQ:FGEN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for FibroGen in a note issued to investors on Tuesday, March 18th. HC Wainwright analyst M. Keller anticipates that the biopharmaceutical company will post earnings per share of $0.04 for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for FibroGen’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at ($0.69) EPS.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $24.91 million.

Separately, StockNews.com started coverage on shares of FibroGen in a research report on Friday, March 14th. They set a “hold” rating on the stock.

FibroGen Trading Down 6.4 %

NASDAQ:FGEN opened at $0.32 on Thursday. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.80. The stock has a market capitalization of $31.74 million, a price-to-earnings ratio of -0.26 and a beta of 0.82. The firm has a fifty day simple moving average of $0.49 and a two-hundred day simple moving average of $0.43.

Hedge Funds Weigh In On FibroGen

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC increased its stake in FibroGen by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 32,884 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of FibroGen by 430.7% during the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,358,194 shares during the last quarter. FMR LLC grew its holdings in shares of FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 68,569 shares during the last quarter. Franklin Street Advisors Inc. NC increased its position in shares of FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of FibroGen by 19.6% in the 4th quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 98,888 shares during the last quarter. 72.71% of the stock is currently owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.